marcha

Fragoso YD, Adoni T, Alves-Leon SV, Apostolos-Pereira SL, Barreira AA, Brooks JB, Claudino R, Correa EC, Ferreira ML, Finkelsztejn A, Finkelsztejn J, da Gama PD, Goncalves MV, Guerreiro CT, da Cunha Matta AP, Marques VD, Rizo Morales R, Parolin MF, de Castro Ribeiro M, Ribeiro TA, Ruocco HH, Sato H...

Año publicación:

2016

Número de revista:

NeuroRehabilitation vol. 39 n. 2

Real-life experience with fampridine (Fampyra®) for patients with multiple sclerosis and gait disorders.

Artículo

Reducing Sitting Time After Stroke: A Phase II Safety and Feasibility Randomized Controlled Trial.

Autor/es:

English C, Healy GN, Olds T, Parfitt G, Borkoles E, Coates A, Kramer S, Bernhardt J.

Año publicación:

2016

Número de revista:

Arch Phys Med Rehabil. vol. 97 n. 2

Reducing Sitting Time After Stroke: A Phase II Safety and Feasibility Randomized Controlled Trial.

Una iniciativa de:

Recursos

Promoting Gait Recovery and Limiting Neuropathic Pain After Spinal Cord Injury.

Propulsive Forces Applied to the Body's Center of Mass Affect Metabolic Energetics Poststroke.

Prospectively Classifying Community Walkers After Stroke: Who Are They?

Provocative Walking Test of Strength for Diagnosis, Management, and Outcome Assessment of Symptomatic Lumbar Spinal Stenosis.

Quantified clinical measures linked to ambulation speed in hemiparesis.

Quantitative Synthesis of Timed 25-Foot Walk Performance in Multiple Sclerosis.

R3-Walk and R6-Walk, Simple Clinical Equations to Accurately Predict Independent Walking at 3 and 6 Months After Stroke: A Prospective, Cohort Study.

Readaptación en la arteriopatía de los miembros inferiores

Real-life experience with fampridine (Fampyra®) for patients with multiple sclerosis and gait disorders.

Reducing Sitting Time After Stroke: A Phase II Safety and Feasibility Randomized Controlled Trial.

¿Crees que falta información? ¡Haznos llegar tus sugerencias!